Briquilimab is a monoclonal antibody commercialized by Jasper Therapeutics, with a leading Phase II program in Severe Combined Immune Deficiency (SCID).

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...

About half of people with "chronic spontaneous urticaria," or CSU, the most common type of chronic hives, experience what ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful case ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of ...

South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...

Dosing of the first patient in our ETESIAN study in asthma is a significant milestone, marking our third clinical program evaluating briquilimab in an inflammatory disease driven by unwanted mast cell ...